The Ibr-7 Derivative of Ibrutinib Exhibits Enhanced Cytotoxicity Against Non-Small Cell Lung Cancer (NSCLC) Cells via Targeting of mTORC1/S6 Signaling

Molecular Oncology - Netherlands
doi 10.1002/1878-0261.12454
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

FAM98A Promotes Proliferation of Non-Small Cell Lung Cancer Cells via the P38-Atf2 Signaling Pathway

Cancer Management and Research
Oncology
2018English

Doxycycline Inhibits Electric Field-Induced Migration of Non-Small Cell Lung Cancer (NSCLC) Cells

Scientific Reports
Multidisciplinary
2019English

MicroRNA-29a Plays a Suppressive Role in Non-Small Cell Lung Cancer Cells via Targeting LASP1

OncoTargets and Therapy
OncologyPharmacology
2016English

Bisphosphonamidate Clodronate Prodrug Exhibits Potent Anticancer Activity in Non-Small-Cell Lung Cancer Cells

Journal of Medicinal Chemistry
Drug DiscoveryMolecular Medicine
2011English

Checkpoint Inhibitors in Squamous Non-Small Cell Lung Cancer (NSCLC)

Open Access Journal of Oncology and Medicine
2018English

Targeting CD47 and Autophagy Elicited Enhanced Antitumor Effects in Non–Small Cell Lung Cancer

Cancer immunology research
Cancer ResearchImmunology
2017English

Long Noncoding RNA PART1 Promotes Progression of Non‐small Cell Lung Cancer Cells via JAK‐STAT Signaling Pathway

Cancer Medicine
Cancer ResearchNuclear MedicineRadiologyImagingOncology
2019English

MicroRNA‐based Biomarkers for Diagnosis of Non‐small Cell Lung Cancer (NSCLC)

Thoracic Cancer
MedicinePulmonaryRespiratory MedicineOncology
2020English

PCN134 Patient Preferences for Non-Small Cell Lung Cancer (NSCLC) Treatments

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy